Pipeline

In our internal R&D projects and in cooperation with our collaborators we are currently developing targeted drSH3 domains for several therapeutic platforms and applications, including:

• Targeting modules for development of novel biologics
• Bispecific derivatives of existing therapeutic antibodies
• Plasma half-life extension of therapeutic proteins and peptides